CTAG1B and melanoma: These combination therapies will include targeting melanoma specific antigens by cancer vaccination or adoptive cell therapy, in conjunction with immune checkpoint inhibition, and indeed this is the focus of several current clinical trials (NCT01176474, NCT02077114, NCT01176461, NCT01988077, NCT01701674), including our own trial combining vaccination with NY-ESO-1 and ipilimumab (NCT01810016).